|
NZ219575A
(en)
|
1986-03-12 |
1990-04-26 |
Glaxo Group Ltd |
Phosphate, substituted alkoxy, or amino-carbonyloxy derivatives of milbemycin, and pesticidal compositions
|
|
US5545618A
(en)
|
1990-01-24 |
1996-08-13 |
Buckley; Douglas I. |
GLP-1 analogs useful for diabetes treatment
|
|
CA2073856C
(en)
|
1990-01-24 |
2002-12-03 |
Douglas I. Buckley |
Glp-1 analogs useful for diabetes treatment
|
|
DK39892D0
(da)
|
1992-03-25 |
1992-03-25 |
Bernard Thorens |
Peptid
|
|
CA2157766A1
(en)
|
1993-03-29 |
1994-10-13 |
Ambikaipakan Balasubramaniam |
Analogs of peptide yy and uses thereof
|
|
US5705483A
(en)
|
1993-12-09 |
1998-01-06 |
Eli Lilly And Company |
Glucagon-like insulinotropic peptides, compositions and methods
|
|
US5968899A
(en)
|
1994-06-03 |
1999-10-19 |
Tsumura & Co. |
Medicinal compositions of peptides with EACA or tranexamic acid for enhanced mucosal absorption
|
|
US5512549A
(en)
|
1994-10-18 |
1996-04-30 |
Eli Lilly And Company |
Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
|
|
US5574010A
(en)
|
1994-11-14 |
1996-11-12 |
The Regents Of The University Of California |
Treatment of pancreatic tumors with peptide YY and analogs thereof
|
|
US5869602A
(en)
|
1995-03-17 |
1999-02-09 |
Novo Nordisk A/S |
Peptide derivatives
|
|
US5866536A
(en)
|
1995-03-31 |
1999-02-02 |
Emisphere Technologies, Inc. |
Compounds and compositions for delivering active agents
|
|
US5650386A
(en)
|
1995-03-31 |
1997-07-22 |
Emisphere Technologies, Inc. |
Compositions for oral delivery of active agents
|
|
BR9604880A
(pt)
|
1995-03-31 |
1998-05-19 |
Emisphere Tech Inc |
Composto composição forma de unidade de dosagem métodos para administração de um agente biologicamente ativo para preparar uma composição para administração de um agente ativo e para preparar um composto e composição farmacológica
|
|
SE9600070D0
(sv)
|
1996-01-08 |
1996-01-08 |
Astra Ab |
New oral pharmaceutical dosage forms
|
|
US7235627B2
(en)
|
1996-08-30 |
2007-06-26 |
Novo Nordisk A/S |
Derivatives of GLP-1 analogs
|
|
IL128332A0
(en)
|
1996-08-30 |
2000-01-31 |
Novo Nordisk As |
GLP-1 derivatives
|
|
US6268343B1
(en)
|
1996-08-30 |
2001-07-31 |
Novo Nordisk A/S |
Derivatives of GLP-1 analogs
|
|
US6458924B2
(en)
|
1996-08-30 |
2002-10-01 |
Novo Nordisk A/S |
Derivatives of GLP-1 analogs
|
|
ES2290799T3
(es)
|
1996-11-12 |
2008-02-16 |
Novo Nordisk A/S |
Uso de peptidos glp-1.
|
|
AU1159897A
(en)
|
1996-11-13 |
1998-06-03 |
University Of Cincinnati, The |
Analogs of peptide yy and uses thereof
|
|
US5773647A
(en)
|
1997-02-07 |
1998-06-30 |
Emisphere Technologies, Inc. |
Compounds and compositions for delivering active agents
|
|
EP0908515A3
(en)
|
1997-09-16 |
2000-04-26 |
Smithkline Beecham Plc |
Pancreatic polypeptide
|
|
DE69942307D1
(de)
|
1998-02-27 |
2010-06-10 |
Novo Nordisk As |
N-terminal veränderte glp-1 abkömmlinge
|
|
DE69942306D1
(de)
|
1998-02-27 |
2010-06-10 |
Novo Nordisk As |
Abkömmlinge von glp-1 analogen
|
|
WO1999043708A1
(en)
|
1998-02-27 |
1999-09-02 |
Novo Nordisk A/S |
Glp-1 derivatives of glp-1 and exendin with protracted profile of action
|
|
EP1056774A1
(en)
|
1998-02-27 |
2000-12-06 |
Novo Nordisk A/S |
N-terminally truncated glp-1 derivatives
|
|
ATE265224T1
(de)
|
1998-02-27 |
2004-05-15 |
Novo Nordisk As |
Glp-1 derivate mit einem helix-gehalt über 25 , die partiell strukturierte mizellenartige aggregate bilden
|
|
US6046167A
(en)
|
1998-03-25 |
2000-04-04 |
University Of Cincinnati |
Peptide YY analogs
|
|
JP2002517483A
(ja)
|
1998-06-08 |
2002-06-18 |
シェーリング コーポレイション |
神経ペプチドy5レセプターアンタゴニスト
|
|
SE9802080D0
(sv)
|
1998-06-11 |
1998-06-11 |
Hellstroem |
Pharmaceutical composition for the treatment of functional dyspepsia and/or irritable bowel syndrome and new use of substances therein
|
|
DE69911975T2
(de)
|
1998-07-31 |
2004-09-09 |
Novo Nordisk A/S |
In-vitro stimulation von beta zellen vermehrung
|
|
MY155270A
(en)
|
1998-09-24 |
2015-09-30 |
Lilly Co Eli |
Use of glp-1 or analogs in treatment of stroke
|
|
PL202367B1
(pl)
|
1998-12-07 |
2009-06-30 |
Sod Conseils Rech Applic |
Związki stanowiące analogi GLP-1, kompozycje zawierające te związki oraz zastosowanie tych związków
|
|
ATE309197T1
(de)
|
1999-02-05 |
2005-11-15 |
Emisphere Tech Inc |
Verfahren zur herstellung alkylierter salicylamide
|
|
ES2301477T3
(es)
|
1999-02-22 |
2008-07-01 |
Merrion Research I Limited |
Forma de dosificacion oral solida que contiene un potenciador.
|
|
AU3240900A
(en)
|
1999-02-22 |
2000-09-04 |
Emisphere Holdings, Inc. |
Solid oral dosage form containing heparin or a heparinoid in combination with a carrier
|
|
US7658938B2
(en)
|
1999-02-22 |
2010-02-09 |
Merrion Reasearch III Limited |
Solid oral dosage form containing an enhancer
|
|
BR0010705A
(pt)
|
1999-04-30 |
2002-02-05 |
Amylin Pharmaceuticals Inc |
Exendinas modificadas e agonistas da exendina
|
|
DE60006100T2
(de)
|
1999-05-17 |
2004-07-01 |
Conjuchem, Inc., Montreal |
Lang wirkende insulinotrope peptide
|
|
US7601691B2
(en)
|
1999-05-17 |
2009-10-13 |
Conjuchem Biotechnologies Inc. |
Anti-obesity agents
|
|
EP1076066A1
(en)
|
1999-07-12 |
2001-02-14 |
Zealand Pharmaceuticals A/S |
Peptides for lowering blood glucose levels
|
|
GB9923436D0
(en)
|
1999-10-04 |
1999-12-08 |
American Home Prod |
Pharmaceutical compositions
|
|
US6793934B1
(en)
|
1999-12-08 |
2004-09-21 |
Shire Laboratories, Inc. |
Solid oral dosage form
|
|
WO2001092206A1
(en)
|
2000-06-02 |
2001-12-06 |
Emisphere Technologies, Inc. |
Method of preparing salicylamides
|
|
US7049283B2
(en)
|
2000-12-06 |
2006-05-23 |
Novartis Ag |
Pharmaceutical compositions for the oral delivery of pharmacologically active agents
|
|
ATE406384T1
(de)
|
2000-12-07 |
2008-09-15 |
Lilly Co Eli |
Glp-1 fusion proteine
|
|
AU2002228608A1
(en)
|
2000-12-13 |
2002-06-24 |
Eli Lilly And Company |
Amidated glucagon-like peptide-1
|
|
RU2275207C2
(ru)
|
2000-12-14 |
2006-04-27 |
Амилин Фармасьютикалз, Инк. |
Способ снижения доступности питательного вещества, способ подавления аппетита
|
|
US6589938B2
(en)
|
2001-06-29 |
2003-07-08 |
National University Of Singapore |
Use of angiotensin I derivatives as an agent for the treatment and prevention of infarction-related cardiac injuries and disorders
|
|
US20030068356A1
(en)
|
2001-07-10 |
2003-04-10 |
Pather S. Indiran |
Sequential drug delivery systems
|
|
AU2002317599B2
(en)
|
2001-07-31 |
2008-04-03 |
The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services |
GLP-1 exendin-4 peptide analogs and uses thereof
|
|
BR0212985A
(pt)
|
2001-09-24 |
2005-08-30 |
Imp College Innovations Ltd |
Uso de pyy ou de um agonista do mesmo na preparação de medicamentos para tratamento de distúrbios associados com excesso de peso
|
|
JP5196701B2
(ja)
|
2001-11-29 |
2013-05-15 |
エミスフィアー テクノロジーズ インコーポレイテッド |
クロモリンナトリウムの経口投与用製剤
|
|
US8058233B2
(en)
|
2002-01-10 |
2011-11-15 |
Oregon Health And Science University |
Modification of feeding behavior using PYY and GLP-1
|
|
EP1478347A1
(en)
|
2002-02-01 |
2004-11-24 |
Pfizer Products Inc. |
Dry granulated formulations of azithromycin
|
|
KR101165431B1
(ko)
|
2002-02-20 |
2012-07-12 |
에미스페어 테크놀로지스, 인코포레이티드 |
Glp-1 분자의 투여 방법
|
|
ES2327328T3
(es)
|
2002-07-04 |
2009-10-28 |
Zealand Pharma A/S |
Glp-1 y procedimientos para el tratamiento de la diabetes.
|
|
JP2004131398A
(ja)
|
2002-10-08 |
2004-04-30 |
Taihei Chemical Industrial Co Ltd |
錠剤用滑沢剤
|
|
WO2004066966A2
(en)
|
2003-01-17 |
2004-08-12 |
Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. |
Peptide yy analogs
|
|
WO2004067548A2
(en)
|
2003-01-31 |
2004-08-12 |
Theratechnologies Inc. |
Chemically modified metabolites of regulatory peptides and methods of producing and using same
|
|
JP2006520818A
(ja)
|
2003-03-19 |
2006-09-14 |
イーライ リリー アンド カンパニー |
ポリエチレングリコール結合glp−1化合物
|
|
WO2004104018A2
(en)
|
2003-05-14 |
2004-12-02 |
Emisphere Technologies, Inc. |
Compositions for delivering peptide yy and pyy agonists
|
|
US7572581B2
(en)
|
2003-06-30 |
2009-08-11 |
Roche Molecular Systems, Inc. |
2′-terminator nucleotide-related methods and systems
|
|
AU2004255458B2
(en)
|
2003-07-11 |
2007-09-13 |
Emisphere Technologies, Inc. |
Orally dosed pharmaceutical compositions comprising a delivery agent in micronized form
|
|
WO2005014035A2
(en)
|
2003-08-08 |
2005-02-17 |
Novo Nordisk Health Care Ag |
Use of galactose oxidase for selective chemical conjugation of protractor molecules to proteins of therapeutic interest
|
|
EP1667724A2
(en)
|
2003-09-19 |
2006-06-14 |
Novo Nordisk A/S |
Albumin-binding derivatives of therapeutic peptides
|
|
CN100444898C
(zh)
|
2003-09-19 |
2008-12-24 |
诺沃挪第克公司 |
治疗肽的清蛋白结合型衍生物
|
|
AU2004273573B2
(en)
|
2003-09-19 |
2010-04-22 |
Novo Nordisk A/S |
Albumin-binding derivatives of therapeutic peptides
|
|
AU2004290862B2
(en)
|
2003-11-20 |
2010-06-03 |
Novo Nordisk A/S |
Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices
|
|
WO2005058954A1
(en)
|
2003-12-18 |
2005-06-30 |
Novo Nordisk A/S |
Novel glp-1 compounds
|
|
MXPA06006746A
(es)
|
2003-12-18 |
2006-08-18 |
Novo Nordisk As |
Analogos de glp-1 novedosos ligados a agentes similares a albumina.
|
|
US20060286129A1
(en)
|
2003-12-19 |
2006-12-21 |
Emisphere Technologies, Inc. |
Oral GLP-1 formulations
|
|
CN102174115B
(zh)
|
2004-02-11 |
2014-05-14 |
安米林药品有限责任公司 |
具有可选择特性的杂合多肽
|
|
JP5638177B2
(ja)
|
2004-02-11 |
2014-12-10 |
アミリン・ファーマシューティカルズ, リミテッド・ライアビリティ・カンパニーAmylin Pharmaceuticals, Llc |
膵臓ポリペプチドファミリーモチーフおよびそのモチーフを含むポリペプチド
|
|
JP2007531713A
(ja)
|
2004-03-17 |
2007-11-08 |
7ティーエム ファーマ エイ/エス |
治療的介入のためのy2選択性レセプターアゴニスト
|
|
CA2560166A1
(en)
|
2004-03-17 |
2005-09-29 |
7Tm Pharma A/S |
Y2/y4 selective receptor agonists for therapeutic interventions
|
|
CN1953763A
(zh)
|
2004-03-17 |
2007-04-25 |
7Tm制药联合股份有限公司 |
用于治疗性干预的y4选择性受体激动剂
|
|
MXPA06010345A
(es)
|
2004-03-17 |
2007-06-19 |
7Tm Pharma As |
Agonistas de receptor selectivo de y4 para intervenciones terapeuticas.
|
|
WO2005099672A1
(en)
|
2004-04-13 |
2005-10-27 |
Ranbaxy Laboratories Limited |
A modified release pharmaceutical formulation comprising amoxicillin and clavulanate
|
|
KR20070008720A
(ko)
|
2004-05-06 |
2007-01-17 |
에미스페어 테크놀로지스, 인코포레이티드 |
습윤 헤파린의 고체 투여형
|
|
CN102040537A
(zh)
|
2004-05-06 |
2011-05-04 |
爱密斯菲尔科技公司 |
N-[8-(2-羟基苯甲酰基)氨基]辛酸一钠的晶体的多晶
|
|
MXPA06013252A
(es)
*
|
2004-05-14 |
2007-02-28 |
Emisphere Tech Inc |
Compuestos y composiciones para suministrar agentes activos.
|
|
GB0412181D0
(en)
|
2004-06-01 |
2004-06-30 |
Celltech R&D Ltd |
Biological products
|
|
WO2005121090A1
(en)
|
2004-06-02 |
2005-12-22 |
Abbott Laboratories |
Substituted piperidines that have antiangiogenic activity
|
|
TW200611704A
(en)
|
2004-07-02 |
2006-04-16 |
Bristol Myers Squibb Co |
Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions
|
|
CN101010339B
(zh)
|
2004-07-02 |
2011-11-09 |
布里斯托尔-迈尔斯斯奎布公司 |
人类胰高血糖素样肽-1调节剂及它们在治疗糖尿病及相关病况中的用途
|
|
AU2005261740A1
(en)
|
2004-07-08 |
2006-01-19 |
Novo Nordisk A/S |
Polypeptide protracting tags comprising a tetrazole moiety
|
|
CN101443028A
(zh)
|
2004-07-12 |
2009-05-27 |
爱密斯菲尔科技公司 |
用于递送肽yy和pyy激动剂的组合物
|
|
WO2006020207A2
(en)
|
2004-07-19 |
2006-02-23 |
University Of Cincinnati |
Compounds for control of appetite
|
|
US20060078623A1
(en)
|
2004-08-13 |
2006-04-13 |
Emisphere Technologies, Inc. |
Pharmaceutical formulations containing microparticles or nanoparticles of a delivery agent
|
|
WO2006049681A2
(en)
|
2004-08-30 |
2006-05-11 |
Bayer Pharmaceuticals Corporation |
Selective neuropeptide y2 receptor agonists
|
|
US8030273B2
(en)
|
2004-10-07 |
2011-10-04 |
Novo Nordisk A/S |
Protracted exendin-4 compounds
|
|
WO2006037810A2
(en)
|
2004-10-07 |
2006-04-13 |
Novo Nordisk A/S |
Protracted glp-1 compounds
|
|
RU2007126522A
(ru)
|
2004-12-09 |
2009-01-20 |
Радиал Корпорэйшин Лимитед (Au) |
Транспортировка материала для радиального пиления древесины
|
|
US7410949B2
(en)
|
2005-01-18 |
2008-08-12 |
Hoffmann-La Roche Inc. |
Neuropeptide-2 receptor (Y-2R) agonists and uses thereof
|
|
WO2006084164A2
(en)
|
2005-02-01 |
2006-08-10 |
Emisphere Technologies, Inc. |
Gastric retention and controlled release delivery system
|
|
EP1846446B1
(en)
|
2005-02-02 |
2013-06-26 |
Novo Nordisk A/S |
Insulin derivatives
|
|
WO2006096515A2
(en)
|
2005-03-04 |
2006-09-14 |
Biorexis Pharmaceutical Corporation |
Modified transferrin fusion proteins
|
|
GB0504857D0
(en)
|
2005-03-09 |
2005-04-13 |
Imp College Innovations Ltd |
Novel compounds and their effects on feeding behaviour
|
|
AU2006224537A1
(en)
|
2005-03-18 |
2006-09-21 |
Novo Nordisk A/S |
Extended GLP-1 compounds
|
|
WO2006097535A2
(en)
|
2005-03-18 |
2006-09-21 |
Novo Nordisk A/S |
Peptide agonists of the glucagon family with secretin like activity
|
|
EP1863537A2
(en)
|
2005-03-18 |
2007-12-12 |
Novo Nordisk A/S |
Dimeric peptide agonists of the glp-1 receptor
|
|
TWI362392B
(en)
*
|
2005-03-18 |
2012-04-21 |
Novo Nordisk As |
Acylated glp-1 compounds
|
|
AU2006228525A1
(en)
|
2005-03-28 |
2006-10-05 |
Dexcel Pharma Technologies Ltd. |
Controlled absorption of statins in the intestine
|
|
EP1883652A2
(en)
|
2005-05-26 |
2008-02-06 |
Bristol-Myers Squibb Company |
N-terminally modified glp-1 receptor modulators
|
|
WO2007008778A2
(en)
|
2005-07-11 |
2007-01-18 |
Nastech Pharmaceutical Company Inc. |
Formulations for enhanced mucosal delivery of pyy
|
|
WO2007011958A2
(en)
|
2005-07-15 |
2007-01-25 |
Emisphere Technologies, Inc. |
Intraoral dosage forms of glucagon
|
|
CN101222942A
(zh)
|
2005-07-18 |
2008-07-16 |
诺沃-诺迪斯克有限公司 |
用于治疗肥胖的肽
|
|
DK3524261T5
(da)
|
2005-08-19 |
2024-09-02 |
Amylin Pharmaceuticals Llc |
Exendin til anvendelse til behandling af diabetes og reduktion af kropsvægt
|
|
US20070049557A1
(en)
|
2005-08-24 |
2007-03-01 |
Hashim Ahmed |
Solid pharmaceutical dosage forms comprising bisphosphonates and modified amino acid carriers
|
|
EA200800874A1
(ru)
|
2005-09-21 |
2008-08-29 |
7ТиЭм ФАРМА А/С |
Рецепторные агонисты, селективные к y4 рецептору, для терапевтического воздействия
|
|
CN101268096A
(zh)
|
2005-09-21 |
2008-09-17 |
7Tm制药联合股份有限公司 |
用于治疗性干预的y2选择性受体激动剂
|
|
WO2007061434A2
(en)
|
2005-11-10 |
2007-05-31 |
Nastech Pharmaceutical Company Inc. |
A pharmaceutical formulation of glp-1 and its use for treating a metabolic syndrome
|
|
WO2007061829A2
(en)
|
2005-11-17 |
2007-05-31 |
Novartis Ag |
Pharmaceutical composition
|
|
WO2007065808A2
(en)
|
2005-12-07 |
2007-06-14 |
F. Hoffmann-La Roche Ag |
Neuropeptide-2 receptor-agonists
|
|
BRPI0620571A2
(pt)
|
2005-12-08 |
2011-11-22 |
Nastech Pharm Co |
formulação farmacêutica aquosa, forma de dosagem de exendina, solução aquosa, uso de uma formulação farmacêutica, e uso de uma formulação farmacêutica aquosa
|
|
WO2007068718A1
(en)
|
2005-12-14 |
2007-06-21 |
Novo Nordisk A/S |
Polypeptide protracting tags
|
|
US20070197445A1
(en)
|
2006-01-18 |
2007-08-23 |
University Of Cincinnati |
Compounds for control of appetite
|
|
JP5412273B2
(ja)
|
2006-03-21 |
2014-02-12 |
アミリン・ファーマシューティカルズ,リミテッド・ライアビリティ・カンパニー |
ペプチド−ぺプチダーゼ阻害剤及びその使用
|
|
US7704977B2
(en)
|
2006-04-07 |
2010-04-27 |
Merrion Research Iii Limited |
Solid oral dosage form containing an enhancer
|
|
US8927015B2
(en)
|
2006-04-12 |
2015-01-06 |
Emisphere Technologies, Inc. |
Formulations for delivering insulin
|
|
WO2007128817A2
(en)
|
2006-05-09 |
2007-11-15 |
Novo Nordisk A/S |
Insulin derivative
|
|
EP2040731A4
(en)
|
2006-06-09 |
2010-05-19 |
Merrion Res Iii Ltd |
SOLID DOSAGE FORM FOR ORAL ADMINISTRATION CONTAINING AN ACTIVATOR
|
|
EP2040718B1
(en)
|
2006-06-28 |
2017-12-27 |
Emisphere Technologies, Inc. |
Gallium nitrate formulations
|
|
GB0613196D0
(en)
|
2006-07-03 |
2006-08-09 |
Imp Innovations Ltd |
Novel compounds and their effects on feeding behaviour
|
|
ES2296529B1
(es)
|
2006-08-07 |
2009-04-01 |
Laboratorios Farmaceuticos Rovi, S.A. |
Composicion farmaceutica con promotores de absorcion.
|
|
US20090318353A1
(en)
|
2006-08-25 |
2009-12-24 |
Novo Nordisk A/S |
Acylated Exendin-4 Compounds
|
|
JP5021033B2
(ja)
|
2006-09-07 |
2012-09-05 |
エフ.ホフマン−ラ ロシュ アーゲー |
Snac(サルカプロザートナトリウム)の製造法
|
|
PE20080840A1
(es)
|
2006-09-13 |
2008-08-27 |
Smithkline Beecham Corp |
Metodos para administrar agentes hipoglucemiantes de larga duracion
|
|
WO2008039351A2
(en)
|
2006-09-22 |
2008-04-03 |
Novartis Ag |
Method of manufacturing tablets containing pharmacologically active agents
|
|
GB0621973D0
(en)
|
2006-11-03 |
2006-12-13 |
Philogen Spa |
Binding molecules and uses thereof
|
|
US20100069410A1
(en)
|
2006-12-01 |
2010-03-18 |
Emisphere Technologies Inc. |
acyclovir formulations
|
|
US20090099074A1
(en)
|
2007-01-10 |
2009-04-16 |
Conjuchem Biotechnologies Inc. |
Modulating food intake
|
|
EP2106405A2
(en)
|
2007-01-18 |
2009-10-07 |
Novo Nordisk A/S |
Peptides for use in the treatment of obesity
|
|
US20100022446A1
(en)
|
2007-01-18 |
2010-01-28 |
Novo Nordisk A/S |
Use of Peptides in Combination with Surgical Intervention for the Treatment of Obesity
|
|
JP5249246B2
(ja)
|
2007-03-02 |
2013-07-31 |
ノバルティス アーゲー |
カルシトニンの経口投与
|
|
GB0708226D0
(en)
|
2007-04-27 |
2007-06-06 |
7Tm Pharma As |
Y-receptor agonists
|
|
EP2514406A1
(en)
|
2007-06-01 |
2012-10-24 |
Novo Nordisk A/S |
Spontaneously dispersible preconcentrates including a peptide drug in a solid or semisolid carrier
|
|
US8835381B2
(en)
|
2007-06-12 |
2014-09-16 |
Glaxosmithkline Llc |
Methods for detecting protein in plasma
|
|
BRPI0814629A2
(pt)
|
2007-07-09 |
2015-01-27 |
Imp Innovations Ltd |
Compostos e seus efeitos sobre o comportamento alimentar
|
|
WO2009032749A2
(en)
|
2007-08-29 |
2009-03-12 |
The Regents Of The University Of Californina |
Salicylanilide modified peptides for use as oral therapeutics
|
|
US20100292133A1
(en)
|
2007-09-05 |
2010-11-18 |
Novo Nordisk A/S |
Truncated glp-1 derivaties and their therapeutical use
|
|
WO2009030771A1
(en)
|
2007-09-05 |
2009-03-12 |
Novo Nordisk A/S |
Peptides derivatized with a-b-c-d- and their therapeutical use
|
|
WO2009030738A1
(en)
|
2007-09-05 |
2009-03-12 |
Novo Nordisk A/S |
Glucagon-like peptide-1 derivatives and their pharmaceutical use
|
|
US20100210559A1
(en)
|
2007-09-11 |
2010-08-19 |
Mondobiotech Laboratories Ag |
Trap-14 as a therapeutic agent
|
|
EP2195034A2
(en)
|
2007-09-27 |
2010-06-16 |
Amylin Pharmaceuticals, Inc. |
Peptide-peptidase inhibitor conjugates and methods of making and using same
|
|
PT2203181T
(pt)
|
2007-10-16 |
2018-05-10 |
Biocon Ltd |
Uma composição farmacêutica sólida para administração por via oral e o seu processo de fabrico
|
|
AU2008318423B2
(en)
|
2007-11-02 |
2013-12-05 |
Emisphere Technologies, Inc. |
Method of treating vitamin B12 deficiency
|
|
US20090124639A1
(en)
|
2007-11-06 |
2009-05-14 |
Emisphere Technologies Inc. |
valacyclovir formulations
|
|
US20100317057A1
(en)
|
2007-12-28 |
2010-12-16 |
Novo Nordisk A/S |
Semi-recombinant preparation of glp-1 analogues
|
|
AU2009248041B2
(en)
|
2008-05-16 |
2013-10-03 |
Novo Nordisk A/S |
Long-acting Y2 and/or Y4 receptor agonists
|
|
CA2734442C
(en)
*
|
2008-08-18 |
2016-08-16 |
Oramed Ltd |
Methods and compositions for oral administration of proteins
|
|
ES2561208T3
(es)
|
2008-09-12 |
2016-02-25 |
Novo Nordisk A/S |
Método de acilación de un péptido o una proteína
|
|
US8299023B2
(en)
|
2008-09-17 |
2012-10-30 |
Hoffmann-La Roche Inc. |
Neuropeptide-2 receptor (Y-2R) agonists
|
|
GB0817067D0
(en)
|
2008-09-18 |
2008-10-22 |
7Tm Pharma As |
Intestinal treatment
|
|
SI2271219T1
(sl)
|
2008-10-15 |
2012-03-30 |
Bayer Cropscience Ag |
Uporaba ditiin tetrakarboksimidov za zdravljenje fitopatogenih glivic
|
|
BRPI0921230A2
(pt)
|
2008-11-05 |
2018-10-30 |
Hoffmann La Roche |
agonistas de receptor de neuropeptídeos-2 (y-2r) e usos dos mesmo.
|
|
CN101463081B
(zh)
|
2009-01-12 |
2012-07-04 |
华东师范大学 |
一种glp-1衍生物
|
|
NZ594044A
(en)
*
|
2009-02-13 |
2014-08-29 |
Boehringer Ingelheim Int |
Antidiabetic medications comprising a dpp-4 inhibitor (linagliptin) optionally in combination with other antidiabetics
|
|
CA2752608A1
(en)
|
2009-02-20 |
2010-08-26 |
Ipsen Pharma S.A.S. |
Cytotoxic conjugates having neuropeptide y receptor binding compound
|
|
ITRM20090347A1
(it)
|
2009-07-03 |
2011-01-04 |
Univ Siena |
Dispositivo di analisi del sistema nervoso centrale attraverso l applicazione di stimoli di diversa natura combinati tra loro e lo studio delle corrispondenti reazioni.
|
|
AR077956A1
(es)
|
2009-09-14 |
2011-10-05 |
Bayer Cropscience Ag |
Combinaciones de compuestos activos
|
|
US20130040877A1
(en)
|
2009-09-18 |
2013-02-14 |
Novo Nordisk A/S |
Long-acting y2 receptor agonists
|
|
JP2013507414A
(ja)
|
2009-10-13 |
2013-03-04 |
エフ.ホフマン−ラ ロシュ アーゲー |
神経ペプチド−2受容体(y−2r)アゴニスト
|
|
CN102905722A
(zh)
|
2009-11-13 |
2013-01-30 |
诺沃—诺迪斯克有限公司 |
长效y2受体激动剂
|
|
EP2512454A2
(en)
|
2009-12-16 |
2012-10-24 |
Nod Pharmaceuticals, Inc. |
Compositions and methods for oral drug delivery
|
|
CN102686607B
(zh)
|
2009-12-16 |
2014-10-29 |
诺沃—诺迪斯克有限公司 |
双酰化glp-1衍生物
|
|
US20110182985A1
(en)
|
2010-01-28 |
2011-07-28 |
Coughlan David C |
Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof
|
|
WO2011109787A1
(en)
|
2010-03-05 |
2011-09-09 |
Conjuchem, Llc |
Methods of administering insulinotropic peptides
|
|
WO2011116139A2
(en)
|
2010-03-16 |
2011-09-22 |
Chiasma Inc. |
Improved pharmaceutical compositions and methods of delivery
|
|
EP2560675A1
(en)
|
2010-04-20 |
2013-02-27 |
Novo Nordisk A/S |
Long-acting gastrin derivatives
|
|
JP5827218B2
(ja)
|
2010-04-30 |
2015-12-02 |
株式会社三和化学研究所 |
生理活性物質等の生体内安定性向上のためのペプチド及び生体内安定性が向上した生理活性物質
|
|
MX366325B
(es)
|
2010-05-05 |
2019-07-05 |
Boehringer Ingelheim Int |
Terapia de combinacion.
|
|
DE202010015867U1
(de)
|
2010-11-25 |
2011-05-05 |
Buchhalter, Thomas |
Elektromechanische Halterung zur Aufnahme von Navigations- und Kommunikationsgeräte im KFZ
|
|
HUE036066T2
(hu)
|
2010-12-16 |
2018-06-28 |
Novo Nordisk As |
GLP-1 agonistát és N-(8-(2-hidroxibenzoil)amino)kaprilsav sóját tartalmazó szilárd készítmények
|
|
GB201101459D0
(en)
|
2011-01-27 |
2011-03-16 |
Imp Innovations Ltd |
Novel compounds and thier effects on fedding behaviour
|
|
EP3225631B1
(en)
|
2011-04-12 |
2019-01-09 |
Novo Nordisk A/S |
Double-acylated glp-1 derivatives
|
|
WO2013009545A1
(en)
|
2011-07-08 |
2013-01-17 |
Amylin Pharmaceuticals, Inc. |
Engineered polypeptides having enhanced duration of action with reduced immunogenicity
|
|
DK2827845T3
(en)
|
2012-03-22 |
2019-04-01 |
Novo Nordisk As |
COMPOSITIONS INCLUDING A PROCEDURE AND PREPARING THEREOF
|
|
JP6356660B2
(ja)
|
2012-03-22 |
2018-07-11 |
ノヴォ ノルディスク アー/エス |
送達剤を含む組成物およびその調製
|
|
HRP20181447T1
(hr)
|
2012-03-22 |
2018-11-02 |
Novo Nordisk A/S |
Pripravci glp-1 peptida i njihova priprava
|
|
WO2013178490A1
(en)
|
2012-05-29 |
2013-12-05 |
Novo Nordisk A/S |
Pancreatic polypeptide compounds and use
|
|
WO2013189988A1
(en)
|
2012-06-20 |
2013-12-27 |
Novo Nordisk A/S |
Tablet formulation comprising a peptide and a delivery agent
|
|
PL3689365T3
(pl)
|
2012-07-01 |
2025-11-12 |
Novo Nordisk A/S |
Zastosowanie peptydów glp-1 o przedłużonym działaniu
|
|
MY172578A
(en)
|
2013-05-02 |
2019-12-03 |
Novo Nordisk As |
Oral dosing of glp-1 compounds
|
|
UY35548A
(es)
|
2013-05-02 |
2014-11-28 |
Glaxosmithkline Ip No 2 Ltd |
Péptidos terapéuticos para el tratamiento de trastornos metabólicos.
|
|
RS59026B1
(sr)
|
2013-11-15 |
2019-08-30 |
Novo Nordisk As |
Selektivna pyy jedinjenja i njihova upotreba
|
|
EP3068795B1
(en)
|
2013-11-15 |
2019-03-06 |
Novo Nordisk A/S |
Hpyy(1-36) having a beta-homoarginine substitution at position 35
|
|
CN114949185A
(zh)
|
2015-02-09 |
2022-08-30 |
安特拉贝欧有限公司 |
骨质疏松症的治疗
|
|
CA2988500A1
(en)
|
2015-06-12 |
2016-12-15 |
Novo Nordisk A/S |
Selective pyy compounds and uses thereof
|
|
CN108135962A
(zh)
|
2015-10-07 |
2018-06-08 |
塞浦路迈德有限责任公司 |
用于口服递送肽类药物的药物制剂
|
|
RS64643B1
(sr)
|
2018-02-02 |
2023-10-31 |
Novo Nordisk As |
Čvrste kompozicije koje sadrže glp-1 agonist i so n-(8-(2-hidroksibenzoil)amino)kaprilne kiseline i lubrikant
|